Short-Term Hesperidin Pretreatment Attenuates Rat Myocardial Ischemia/Reperfusion Injury by Inhibiting High Mobility Group Box 1 Protein Expression via the PI3K/Akt Pathway

Cellular Physiology and Biochemistry

Volumn 39, Issue 5, 2016, Pages 1850-1862

  Li, Xuefei ^a,b,c   Hu, Xiaorong ^a,b,c   Wang, Jichun ^a,b,c   Xu, Weipan ^d   Yi, Chunfeng ^a,b,c   Ma, Ruisong ^a,b,c   Jiang, Hong ^a,b,c  

^a RENMIN HOSPITAL OF WUHAN UNIVERSITY   (China)

^b WUHAN UNIVERSITY   (China)

^c HUBEI KEY LABORATORY OF CARDIOLOGY   (China)

^d HUBEI POLYTECHNIC UNIVERSITY   (China)

Author keywords

Hesperidin; High mobility group box 1 protein; Myocardial ischemia reperfusion injury; PI3K Akt

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; CREATINE KINASE; HESPERIDIN; HIGH MOBILITY GROUP B1 PROTEIN; LACTATE DEHYDROGENASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN BAX; PROTEIN BCL 2; 2-(4-MORPHOLINYL)-8-PHENYL-4H-1-BENZOPYRAN-4-ONE; ANTIOXIDANT; CARDIOTONIC AGENT; CHROMONE DERIVATIVE; HBP1 PROTEIN, RAT; MORPHOLINE DERIVATIVE; NONSTEROID ANTIINFLAMMATORY AGENT; PROTEIN KINASE B;

ANIMAL EXPERIMENT; APOPTOSIS; ARTICLE; CARDIAC MUSCLE; CONTROLLED STUDY; DOWN REGULATION; HEART PROTECTION; HISTOPATHOLOGY; LACTATE DEHYDROGENASE BLOOD LEVEL; MALE; MYOCARDIAL ISCHEMIA REPERFUSION INJURY; NONHUMAN; OPTIMAL DRUG DOSE; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; UPREGULATION; ANIMAL; ANTAGONISTS AND INHIBITORS; DOSE CALCULATION; DRUG ADMINISTRATION; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MYOCARDIAL REPERFUSION INJURY; PATHOLOGY; SPRAGUE DAWLEY RAT;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIOXIDANTS; APOPTOSIS; CARDIOTONIC AGENTS; CHROMONES; DRUG ADMINISTRATION SCHEDULE; DRUG DOSAGE CALCULATIONS; GENE EXPRESSION REGULATION; HESPERIDIN; HMGB1 PROTEIN; MALE; MORPHOLINES; MYOCARDIAL REPERFUSION INJURY; MYOCARDIUM; OXIDATIVE STRESS; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-AKT; RATS; RATS, SPRAGUE-DAWLEY; SIGNAL TRANSDUCTION;

EID: 84991761826     PISSN: 10158987     EISSN: 14219778     Source Type: Journal    
DOI: 10.1159/000447884     Document Type: Article

References (50)

1. Wang W, Hu SS, Kong LZ, Gao RL, Zhu ML, Wang WY, Wu ZS, Chen WW, Yang JG, Ma LY, Liu MB, Editorial B: Summary of report on cardiovascular diseases in China, 2012. Biomed Environ Sci 2014;27:552-558.
2. Yellon DM, Hausenloy DJ: Myocardial reperfusion injury. N Engl J Med 2007;357:1121-1135.
3. Keeley EC, Boura JA, Grines CL: Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet 2003;361:13-20.
4. Wei D, Ci X, Chu X, Wei M, Hua S, Deng X: Hesperidin suppresses ovalbumin-induced airway inflammation in a mouse allergic asthma model. Inflammation 2012;35:114-121.
5. Selvaraj P, Pugalendi KV: Hesperidin, a flavanone glycoside, on lipid peroxidation and antioxidant status in experimental myocardial ischemic rats. Redox Rep 2010;15:217-223.
6. Petrova A, Davids LM, Rautenbach F, Marnewick JL: Photoprotection by honeybush extracts, hesperidin and mangiferin against UVB-induced skin damage in SKH-1 mice. Journal of Photochemistry and Photobiology B: Biology 2011;103:126-139.
7. Yumnam S, Hong GE, Raha S, Venkatarame Gowda Saralamma V, Lee HJ, Lee WS, Kim EH, Kim GS: Mitochondrial Dysfunction and Ca Overload Contributes to Hesperidin Induced Paraptosis in Hepatoblastoma Cells, HepG2. J Cell Physiol 2015;10.1002/jcp.25222.
8. Gandhi C, Upaganalawar A, Balaraman R: Protection againstin vivofocal myocardial ischemia/reperfusion injury-induced arrhythmias and apoptosis byHesperidin. Free Radical Research 2009;43:817-827.
9. Rong Z, Pan R, Xu Y, Zhang C, Cao Y, Liu D: Hesperidin pretreatment protects hypoxia-ischemic brain injury in neonatal rat. Neuroscience 2013;255:292-299.
10. Scaffidi P, Misteli T, Bianchi ME: Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature 2002;418:191-195.
11. Bell CW, Jiang W, Reich CF, 3rd, Pisetsky DS: The extracellular release of HMGB1 during apoptotic cell death. Am J Physiol Cell Physiol 2006;291:C1318-1325.
12. Hu X, Jiang H, Bai Q, Zhou X, Xu C, Lu Z, Cui B, Wen H: Increased serum HMGB1 is related to the severity of coronary artery stenosis. Clin Chim Acta 2009;406:139-142.
13. Wang H, Bloom 0, Zhang M, Vishnubhakat JM, Ombrellino M, Che J, Frazier A, Yang H, Ivanova S, Borovikova L, Manogue KR, Faist E, Abraham E, Andersson J, Andersson U, Molina PE, Abumrad NN, Sama A, Tracey KJ: HMG-1 as a late mediator of endotoxin lethality in mice. Science 1999;285:248-251.
14. Andrassy M, Volz HC, Igwe JC, Funke B, Eichberger SN, Kaya Z, Buss S, Autschbach F, Pleger ST, Lukic IK, Bea F, Hardt SE, Humpert PM, Bianchi ME, Mairbaurl H, Nawroth PP, Remppis A, Katus HA, Bierhaus A: High-mobility group box-1 in ischemia-reperfusion injury of the heart. Circulation 2008;117:3216-3226.
15. Hu X, Zhou X, He B, Xu C, Wu L, Cui B, Wen H, Lu Z, Jiang H: Minocycline protects against myocardial ischemia and reperfusion injury by inhibiting high mobility group box 1 protein in rats. Eur J Pharmacol 2010;638:84-89.
16. Hu X, Cui B, Zhou X, Xu C, Lu Z, Jiang H: Ethyl pyruvate reduces myocardial ischemia and reperfusion injury by inhibiting high mobility group box 1 protein in rats. Mol Biol Rep 2012;39:227-231.
17. Kawaguchi K, Kikuchi S, Hasunuma R, Maruyama H, Yoshikawa T, Kumazawa Y: A citrus flavonoid hesperidin suppresses infection-induced endotoxin shock in mice. Biol Pharm Bull 2004;27:679-683.
18. Wymann MP, Zvelebil M, Laffargue M: Phosphoinositide 3-kinase signalling-which way to target? Trends Pharmacol Sci 2003;24:366-376.
19. Wu H, Ye M, Yang J, Ding J, Yang J, Dong W, Wang X: Nicorandil Protects the Heart from Ischemia/Reperfu-sion Injury by Attenuating Endoplasmic Reticulum Response-induced Apoptosis Through PI3K/Akt Signaling Pathway. Cell Physiol Biochem 2015;35:2320-2332.
20. Shanmuganathan S, Hausenloy DJ, Duchen MR, Yellon DM: Mitochondrial permeability transition pore as a target for cardioprotection in the human heart. Am J Physiol Heart Circ Physiol 2005;289:H237-242.
21. Iliodromitis K, Farmakis D, Andreadou I, Zoga A, Bibli SI, Manolaki T, Dagres N, Iliodromitis EK, Anastasiou-Nana M, Kremastinos DT: Various models of cardiac conditioning in single or sequential periods of ischemia: comparative effects on infarct size and intracellular signaling. Int J Cardiol 2013;168:1336-1341.
22. Wolfrum S, Dendorfer A, Schutt M, Weidtmann B, Heep A, Tempel K, Klein HH, Dominiak P, Richardt G: Simvastatin acutely reduces myocardial reperfusion injury in vivo by activating the phosphatidylinositide 3-kinase/Akt pathway. J Cardiovasc Pharmacol 2004;44:348-355.
23. Wang J, Yang H, Hu X, Fu W, Xie J, Zhou X, Xu W, Jiang H: Dobutamine-mediated heme oxygenase-1 induction via PI3K and p38 MAPK inhibits high mobility group box 1 protein release and attenuates rat myocardial ischemia/reperfusion injury in vivo. J Surg Res 2013;183:509-516.
24. Nones J, Costa AP, Leal RB, Gomes FCA, Trentin AG: The flavonoids hesperidin and rutin promote neural crest cell survival. Cell and Tissue Research 2012;350:305-315.
25. Aneja R, Hake PW, Burroughs TJ, Denenberg AG, Wong HR, Zingarelli B: Epigallocatechin, a green tea polyphenol, attenuates myocardial ischemia reperfusion injury in rats. Mol Med 2004;10:55-62.
26. Ruisong M, Xiaorong H, Gangying H, Chunfeng Y, Changjiang Z, Xuefei L, Yuanhong L, Hong J: The Protective Role of Interleukin-33 in Myocardial Ischemia and Reperfusion Is Associated with Decreased HMGB1 Expression and Up-Regulation of the P38 MAPK Signaling Pathway. PLoS One 2015;10:e0143064.
27. Yang J, Jiang H, Yang J, Ding JW, Chen LH, Li S, Zhang XD: Valsartan preconditioning protects against myocardial ischemia-reperfusion injury through TLR4/NF-kappaB signaling pathway. Mol Cell Biochem 2009;330:39-46.
28. Mink PJ, Scrafford CG, Barraj LM, Harnack L, Hong CP, Nettleton JA, Jacobs DR, Jr.: Flavonoid intake and cardiovascular disease mortality: a prospective study in postmenopausal women. Am J Clin Nutr 2007;85:895-909.
29. Wu HJ, Yang JY, Jin M, Wang SQ, Wu DL, Liu YN, Yan X, Yang C, Zhang G, He J: Glycyrrhetinic Acid protects the heart from ischemia/reperfusion injury by attenuating the susceptibility and incidence of fatal ventricular arrhythmia during the reperfusion period in the rat hearts. Cell Physiol Biochem 2015;36:741-752.
30. Morand C, Dub ray C, Milenkovic D, Lioger D, Martin JF, Scalbert A, Mazur A: Hesperidin contributes to the vascular protective effects of orange juice: a randomized crossover study in healthy volunteers. Am J Clin Nutr 2011;93:73-80.
31. Reagan-Shaw S, Nihal M, Ahmad N: Dose translation from animal to human studies revisited. FASEB J 2008;22:659-661.
32. Agrawal YO, Sharma PK, Shrivastava B, Ojha S, Upadhya HM, Arya DS, Goyal SN: Hesperidin produces cardioprotective activity via PPAR-gamma pathway in ischemic heart disease model in diabetic rats. PLoS One 2014;9:elll212.
33. Frangogiannis NG, Smith CW, Entman ML: The inflammatory response in myocardial infarction. Cardiovasc Res 2002;53:31-47.
34. Gottlieb RA, Engler RL: Apoptosis in myocardial ischemia-reperfusion. Ann N Y Acad Sci 1999;874:412-426.
35. Zhai CL, Zhang MQ, Zhang Y, Xu HX, Wang JM, An GP, Wang YY, Li L: Glycyrrhizin protects rat heart against ischemia-reperfusion injury through blockade of HMGBl-dependent phospho-JNK/Bax pathway. Acta Pharmacol Sin 2012;33:1477-1487.
36. Agrawal YO, Sharma PK, Shrivastava B, Arya DS, Goyal SN: Hesperidin blunts streptozotocin-isoproternol induced myocardial toxicity in rats by altering of PPAR-gamma receptor. Chem Biol Interact 2014;219:211-220.
37. Steffens S, Montecucco F, Mach F: The inflammatory response as a targetto reduce myocardial ischaemia and reperfusion injury. Thromb Haemost 2009;102:240-247.
38. Wang Y, Sun J, Liu C, Fang C: Protective effects of crocetin pretreatment on myocardial injury in an ischemia/reperfusion rat model. Eur J Pharmacol 2014;741:290-296.
39. Yamada S, Maruyama I: HMGB1, a novel inflammatory cytokine. Clin Chim Acta 2007;375:36-42.
40. Yang H, Wang H, Czura CJ, Tracey KJ: The cytokine activity of HMGB1. J Leukoc Biol 2005;78:1-8.
41. Andersson U, Wang H, Palmblad K, Aveberger AC, Bloom 0, Erlandsson-Harris H, Janson A, Kokkola R Zhang M, Yang H, Tracey KJ: High mobility group 1 protein (HMG-1) stimulates proinflammatory cytokine synthesis in human monocytes. J Exp Med 2000;192:565-570.
42. Inoue K, Kawahara K, Biswas KK, Ando K, Mitsudo K, Nobuyoshi M, Maruyama I: HMGB1 expression by activated vascular smooth muscle cells in advanced human atherosclerosis plaques. Cardiovasc Pathol 2007;16:136-143.
43. Zhang ZW, Zhang QY, Zhou MT, Liu NX, Chen TK, Zhu YF, Wu L: Antioxidant inhibits HMGB1 expression and reduces pancreas injury in rats with severe acute pancreatitis. Dig Dis Sci 2010;55:2529-2536.
44. Chae HJ, Kim HR, Bae J, Chae SU, Ha KC, Chae SW: Signal transduction of the protective effect of insulin like growth factor-1 on adriamycin-induced apoptosis in cardiac muscle cells. Arch Pharm Res 2004;27:324-333.
45. Cao CM, Zhang Y, Weisleder N, Ferrante C, Wang X, Lv F, Zhang Y, Song R, Hwang M, Jin L, Guo J, Peng W, Li G, Nishi M, Takeshima H, Ma J, Xiao RP: MG53 constitutes a primary determinant of cardiac ischemic preconditioning. Circulation 2010;121:2565-2574.
46. Wang B, Shravah J, Luo H, Raedschelders K, Chen DD, Ansley DM: Propofol protects against hydrogen peroxide-induced injury in cardiac H9c2 cells via Akt activation and Bcl-2 up-regulation. Biochem Biophys Res Commun 2009;389:105-111.
47. Cohen MV, Downey JM: Signalling pathways and mechanisms of protection in pre-and postconditioning: historical perspective and lessons for the future. Br J Pharmacol 2015;172:1913-1932.
48. Andreadou I, Farmakis D, Prokovas E, Sigala F, Zoga A, Spyridaki K, Papalois A, Papapetropoulos A, Anasta-siou-Nana M, Kremastinos DT, Iliodromitis EK: Short-term statin administration in hypercholesterolaemic rabbits resistant to postconditioning: effects on infarct size, endothelial nitric oxide synthase, and nitro-oxidative stress. Cardiovasc Res 2012;94:501-509.
49. Zhao MM, Yang JY, Wang XB, Tang CS, Du JB, Jin HF: The PI3K/Akt pathway mediates the protection of S0(2) preconditioning against myocardial ischemia/reperfusion injury in rats. Acta Pharmacol Sin 2013;34:501-506.
50. Andreadou I, Iliodromitis EK, Tsovolas K, Aggeli IK, Zoga A, Gaitanaki C, Paraskevaidis IA, Markantonis SL, Beis I, Kremastinos DT: Acute administration of vitamin E triggers preconditioning via K(ATP) channels and cyclic-GMP without inhibiting lipid peroxidation. Free Radic Biol Med 2006;41:1092-1099.